SOPHiA GENETICS SA (SOPH) News
NASDAQ: SOPHTechnologyEDP ServicesUSD
7.41+0.11 (+1.51%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SOPH news summary
We found 2 recent headlines mentioning SOPHiA GENETICS SA (SOPH): 2 in the past week and 2 in the past 30 days, most often from Nasdaq. For price context, SOPH is up 1.51% at $7.41. The most recent story, "Myriad Genetics, SOPHiA GENETICS Partner With AstraZeneca On Prostate Cancer PrGIS", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest SOPHiA GENETICS SA headlines
- Myriad Genetics, SOPHiA GENETICS Partner With AstraZeneca On Prostate Cancer PrGIS(RTTNews) - Myriad Genetics (MYGN) and SOPHiA GENETICS (SOPH) announced a collaboration with AstraZeneca (AZN) to advance a new prostate cancer-specific genomic instability score, or PrGIS, for…NasdaqAZN, MYGN, SOPH
- SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology(RTTNews) - SOPHiA GENETICS (SOPH) and Myriad Genetics, Inc. (MYGN) announced Thursday a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support…NasdaqMYGN, SOPH